Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)

NCT04655625 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: Group A (AG0302-COVID19)
BIOLOGICAL: Group A (Placebo)
BIOLOGICAL: Group B (AG0302-COVID19)
BIOLOGICAL: Group B (Placebo)

Sponsor

AnGes, Inc.

Collaborators

[object Object]